MIDATECH PHARMA
R&D | Q-Octreotide

Q-Octreotide for Acromegaly and Carcinoid Syndrome

Acromegaly is a rare condition that results from over-production of growth hormone that causes severe disfigurement and can be fatal if not treated. Octreotide, formulated as Sandostatin LAR (SLAR) for sustained release, is used to decrease the production of growth hormone in people suffering from acromegaly who failed to respond to, or were not suitable for, surgery. SLAR is also an important treatment for carcinoid syndrome that occurs as a result of carcinoid tumours (ie hormone-producing tumours). Q-Octreotide is being developed as an alternative to SLAR. The imroved sustained release formulation used in Q-Octreotide allows the use of smaller needles, which is expected to improve patient satisfaction by reducing pain vs SLAR. Similarly, quicker and simpler reconstitution will reduce the nurse/ physician time to administer. Payers will benefit from improved economics by way of a reduction in direct medical costs such as lower drug cost, less wasted dosages and a reduced administration time.

This project is expected to commence a Pilot study to compare the pharmacokinetics of Q-Octreotide versus Sandostatin LAR in humans during 1H 2017, followed by potential regulatory filings in 2017/18 and possible market approvals in the United States and the European Union in late 2018/19. Midatech intends to partner this program globally prior to commercialisation, but will co-promote the Carcinoid indication in the US.

R&D
R&D
Q-Octreotide

Q-Octreotide for Acromegaly and Carcinoid Syndrome

Acromegaly is a rare condition that results from over-production of growth hormone that causes severe disfigurement and can be fatal if not treated. Octreotide, formulated as Sandostatin LAR (SLAR) for sustained release, is used to decrease the production of growth hormone in people suffering from acromegaly who failed to respond to, or were not suitable for, surgery. SLAR is also an important treatment for carcinoid syndrome that occurs as a result of carcinoid tumours (ie hormone-producing tumours). Q-Octreotide is being developed as an alternative to SLAR. The imroved sustained release formulation used in Q-Octreotide allows the use of smaller needles, which is expected to improve patient satisfaction by reducing pain vs SLAR. Similarly, quicker and simpler reconstitution will reduce the nurse/ physician time to administer. Payers will benefit from improved economics by way of a reduction in direct medical costs such as lower drug cost, less wasted dosages and a reduced administration time.

This project is expected to commence a Pilot study to compare the pharmacokinetics of Q-Octreotide versus Sandostatin LAR in humans during 1H 2017, followed by potential regulatory filings in 2017/18 and possible market approvals in the United States and the European Union in late 2018/19. Midatech intends to partner this program globally prior to commercialisation, but will co-promote the Carcinoid indication in the US.

© Copyright 2017 Midatech Pharma PLC